Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Multiple Cancer Types
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Lung,
Small Cell
III
Iams, Wade
NCT03703297
VICCTHO1901
Molecular Predictors of Lung Cancer Behavior. (SPORE)
Multiple Cancer Types
Lung,
Non Small Cell,
Small Cell
N/A
Massion, Pierre
NCT00898313
VICCTHO0398
